One Goal: providing easy and affordable access to simple and convenient tests to monitor your health and allow you peace of mind #BeatCancerEarly#Stage4NoMore
Happy New Year! We are excited for what 2023 has in store for #HelioGenomics. Our mission is to save lives by detecting cancer early and to provide peace of mind for you and your families. #2023 #cancerdetection
Are you up to date with your early cancer detection guidelines? Studies show that Helio’s criteria to select & investigate certain genes is more robust and precise, suggesting HelioLiver’s markers are more biologically relevant than competitor tests that utilize other genes.
One of our biggest accomplishments this year has been our ENCORE publication in Hepatology Communications. Read the full journal article here: https://t.co/5xXTfJnZBw
Our CEO, Justin Chen Li was recently interviewed by @SinanKanatsiz with the @IMA_Network . Click the link to watch the full interview and get an inside scoop on what the future looks like for Helio Genomics. Link here: https://t.co/OzIsVDLmZP #cancerdetection#AI#HelioGenomics
Our CEO, Justin Chen Li, was interviewed in Park City, Utah at #IMPACT22. Justin speaks about the origin of #HelioGenomics and how to use artificial intelligence to effectively detect cancer. Watch the video to learn more! https://t.co/dad5HEx05o
Happy Thanksgiving from Helio Genomics! We're grateful to have a hardworking organization dedicated to saving lives through early cancer detection and to be working with dedicated physicians who believe in our cause. #Thanksgiving#HelioGenomics
#HelioLiver is a DNA-based test that examines a person’s specific genetic markup. When cells shed DNA into the bloodstream, that becomes “cell-free DNA”, or cfDNA. HelioLiver utilizes innovative new technology to isolate cfDNA from blood samples and analyzes for signs of cancer.
HelioLiver offers a reliable and accessible approach to testing as a simple blood draw and has been validated in clinical studies with promising results. #HelioLiver#HelioGenomics
As #LiverCancerAwarenessMonth comes to an end, do not forget to tune into the live Webinar this Friday, October 28, at 11am PT as Dr. Robert Gish shares on HCC and the importance of liver surveillance. Register here: https://t.co/2WpzDudLfY #Webinar#HelioLiver#HelioGenomics
Not only is October the awareness month for breast cancer, but also liver cancer. For #LiverCancerAwarenessMonth Justin Li tells us everything we need to know about liver cancer in a recent article. Click the link to read more! https://t.co/DOdU0yjO6g #HelioGenomics#HelioLiver
October is Liver Cancer Awareness Month! Join our live webinar this Friday with Dr. Robert Gish. This webinar will inform both physicians and patients on how HelioLiver can drive early detection of HCC. Register here! https://t.co/2WpzDudLfY #LiverCancerAwarenessMonth
Join our live #webinar next Friday as Dr. Gish, Professor of Medicine at Loma Linda University, shares on Hepatocellular Carcinoma (HCC) and the importance of liver surveillance. Register at: https://t.co/oum6bdGz2v. #LiverCancerAwarenessMonth#HelioLiver
With the HelioLiver cancer test on the market, Helio’s development pipeline is now focused on colon, breast and lung cancer. Our AI-based methods in cancer detection are based on research and development leveraging an extensive data bank for validation. #HelioGenomics
At HelioLiver we are redefining how we find and fight liver cancer by simplifying testing for you and your patients. Now, efficiently test more patients with one simple, affordable blood test that integrates seamlessly with in-office patient care. #HelioLiver#HelioGenomics
Helio Genomics has been named one of the best Tech Start-ups in Irvine, CA by the Tech Tribune. Factors considered in the development of this list of 11 innovative companies include Revenue potential, Leadership team, Brand/product traction and Competitive landscape.
Elevating the Standard of Care: Compared to traditional early liver cancer detection methods, HelioLiver has shown improvements across the board. #HelioLiver#HelioGenomics#cancertesting